251 related articles for article (PubMed ID: 11290585)
61. CBFbeta is critical for AML1-ETO and TEL-AML1 activity.
Roudaia L; Cheney MD; Manuylova E; Chen W; Morrow M; Park S; Lee CT; Kaur P; Williams O; Bushweller JH; Speck NA
Blood; 2009 Mar; 113(13):3070-9. PubMed ID: 19179469
[TBL] [Abstract][Full Text] [Related]
62. The PEBP2beta/CBF beta-SMMHC chimeric protein is localized both in the cell membrane and nuclear subfractions of leukemic cells carrying chromosomal inversion 16.
Kanto S; Chiba N; Tanaka Y; Fujita S; Endo M; Kamada N; Yoshikawa K; Fukuzaki A; Orikasa S; Watanabe T; Satake M
Leukemia; 2000 Jul; 14(7):1253-9. PubMed ID: 10914550
[TBL] [Abstract][Full Text] [Related]
63. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta.
Tahirov TH; Inoue-Bungo T; Morii H; Fujikawa A; Sasaki M; Kimura K; Shiina M; Sato K; Kumasaka T; Yamamoto M; Ishii S; Ogata K
Cell; 2001 Mar; 104(5):755-67. PubMed ID: 11257229
[TBL] [Abstract][Full Text] [Related]
64. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia.
Liu P; Tarlé SA; Hajra A; Claxton DF; Marlton P; Freedman M; Siciliano MJ; Collins FS
Science; 1993 Aug; 261(5124):1041-4. PubMed ID: 8351518
[TBL] [Abstract][Full Text] [Related]
65. The role of the AML1 transcription factor in leukemogenesis.
Lorsbach RB; Downing JR
Int J Hematol; 2001 Oct; 74(3):258-65. PubMed ID: 11721960
[TBL] [Abstract][Full Text] [Related]
66. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.
Okuda T; van Deursen J; Hiebert SW; Grosveld G; Downing JR
Cell; 1996 Jan; 84(2):321-30. PubMed ID: 8565077
[TBL] [Abstract][Full Text] [Related]
67. Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice.
Illendula A; Pulikkan JA; Zong H; Grembecka J; Xue L; Sen S; Zhou Y; Boulton A; Kuntimaddi A; Gao Y; Rajewski RA; Guzman ML; Castilla LH; Bushweller JH
Science; 2015 Feb; 347(6223):779-84. PubMed ID: 25678665
[TBL] [Abstract][Full Text] [Related]
68. Transcription factors that regulate growth and differentiation of myeloid cells.
Nagamura-Inoue T; Tamura T; Ozato K
Int Rev Immunol; 2001 Feb; 20(1):83-105. PubMed ID: 11342299
[TBL] [Abstract][Full Text] [Related]
69. Alterations of the AML1 transcription factor in human leukemia.
Downing JR; Higuchi M; Lenny N; Yeoh AE
Semin Cell Dev Biol; 2000 Oct; 11(5):347-60. PubMed ID: 11105899
[TBL] [Abstract][Full Text] [Related]
70. NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.
Xue L; Pulikkan JA; Valk PJ; Castilla LH
Blood; 2014 Jul; 124(3):426-36. PubMed ID: 24894773
[TBL] [Abstract][Full Text] [Related]
71. Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding subunit of the transcription factor, polyomavirus enhancer binding protein 2/core binding factor.
Niki M; Okada H; Takano H; Kuno J; Tani K; Hibino H; Asano S; Ito Y; Satake M; Noda T
Proc Natl Acad Sci U S A; 1997 May; 94(11):5697-702. PubMed ID: 9159135
[TBL] [Abstract][Full Text] [Related]
72. Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11.
Hyde RK; Kamikubo Y; Anderson S; Kirby M; Alemu L; Zhao L; Liu PP
Blood; 2010 Feb; 115(7):1433-43. PubMed ID: 20007544
[TBL] [Abstract][Full Text] [Related]
73. Methylation-independent silencing of the tumor suppressor INK4b (p15) by CBFbeta-SMMHC in acute myelogenous leukemia with inv(16).
Markus J; Garin MT; Bies J; Galili N; Raza A; Thirman MJ; Le Beau MM; Rowley JD; Liu PP; Wolff L
Cancer Res; 2007 Feb; 67(3):992-1000. PubMed ID: 17283131
[TBL] [Abstract][Full Text] [Related]
74. The transcriptionally active form of AML1 is required for hematopoietic rescue of the AML1-deficient embryonic para-aortic splanchnopleural (P-Sp) region.
Goyama S; Yamaguchi Y; Imai Y; Kawazu M; Nakagawa M; Asai T; Kumano K; Mitani K; Ogawa S; Chiba S; Kurokawa M; Hirai H
Blood; 2004 Dec; 104(12):3558-64. PubMed ID: 15271791
[TBL] [Abstract][Full Text] [Related]
75. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.
Tanaka K; Tanaka T; Kurokawa M; Imai Y; Ogawa S; Mitani K; Yazaki Y; Hirai H
Blood; 1998 Mar; 91(5):1688-99. PubMed ID: 9473235
[TBL] [Abstract][Full Text] [Related]
76. Regulation of hemangioblast development.
Lacaud G; Robertson S; Palis J; Kennedy M; Keller G
Ann N Y Acad Sci; 2001 Jun; 938():96-107; discussion 108. PubMed ID: 11458531
[TBL] [Abstract][Full Text] [Related]
77. Emerging therapies for inv(16) AML.
Surapally S; Tenen DG; Pulikkan JA
Blood; 2021 May; 137(19):2579-2584. PubMed ID: 33821975
[TBL] [Abstract][Full Text] [Related]
78. The RUNX1 Runt domain at 1.25A resolution: a structural switch and specifically bound chloride ions modulate DNA binding.
Bäckström S; Wolf-Watz M; Grundström C; Härd T; Grundström T; Sauer UH
J Mol Biol; 2002 Sep; 322(2):259-72. PubMed ID: 12217689
[TBL] [Abstract][Full Text] [Related]
79. Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation.
Huang G; Shigesada K; Ito K; Wee HJ; Yokomizo T; Ito Y
EMBO J; 2001 Feb; 20(4):723-33. PubMed ID: 11179217
[TBL] [Abstract][Full Text] [Related]
80. CBFβ and RUNX1 are required at 2 different steps during the development of hematopoietic stem cells in zebrafish.
Bresciani E; Carrington B; Wincovitch S; Jones M; Gore AV; Weinstein BM; Sood R; Liu PP
Blood; 2014 Jul; 124(1):70-8. PubMed ID: 24850758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
